LLY

1,065.36

-0.14%↓

JNJ

229.36

-2.22%↓

ABBV

213.32

-1.3%↓

UNH

377.91

-2.64%↓

AZN

187.85

+0.32%↑

LLY

1,065.36

-0.14%↓

JNJ

229.36

-2.22%↓

ABBV

213.32

-1.3%↓

UNH

377.91

-2.64%↓

AZN

187.85

+0.32%↑

LLY

1,065.36

-0.14%↓

JNJ

229.36

-2.22%↓

ABBV

213.32

-1.3%↓

UNH

377.91

-2.64%↓

AZN

187.85

+0.32%↑

LLY

1,065.36

-0.14%↓

JNJ

229.36

-2.22%↓

ABBV

213.32

-1.3%↓

UNH

377.91

-2.64%↓

AZN

187.85

+0.32%↑

LLY

1,065.36

-0.14%↓

JNJ

229.36

-2.22%↓

ABBV

213.32

-1.3%↓

UNH

377.91

-2.64%↓

AZN

187.85

+0.32%↑

Home・Lista de Ações・Ovid therapeutics Inc

Ovid therapeutics Inc

Abrir

SetorSaúde

2.47

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.42

Máximo

2.4699999999999998

Indicadores-chave
By Trading Economics
Rendimento	-27M -17M
Vendas	586K 718K
EPS	-0.125
Margem de lucro	-2,366.017
Funcionários	23
EBITDA	-5.5M -18M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+115.79% upside

Dividendos
By Dow Jones
Próximos Ganhos	12 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-25M 458M
Abertura anterior	2.47
Fecho anterior	2.47

Sentimento de Notícias

By Acuity

50%

159 / 345 Ranking em Healthcare

Ovid therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de mai. de 2026, 08:24 UTC

Grandes Movimentos do Mercado

Aquisições, Fusões, Aquisições de Empresas

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 de mai. de 2026, 21:22 UTC

Ganhos

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Basic Materials Roundup: Market Talk

25 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Ganhos

Basic Materials Roundup: Market Talk

25 de mai. de 2026, 16:01 UTC

Conversa de Mercado

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 de mai. de 2026, 14:43 UTC

Conversa de Mercado

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 de mai. de 2026, 14:15 UTC

Conversa de Mercado

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 de mai. de 2026, 13:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

25 de mai. de 2026, 12:58 UTC

Conversa de Mercado

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 de mai. de 2026, 12:56 UTC

Conversa de Mercado

Ganhos

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 de mai. de 2026, 12:48 UTC

Conversa de Mercado

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 de mai. de 2026, 12:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 de mai. de 2026, 12:34 UTC

Conversa de Mercado

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 de mai. de 2026, 12:10 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Delivery Hero's Assets Look Strategic -- Market Talk

25 de mai. de 2026, 11:00 UTC

Conversa de Mercado

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 de mai. de 2026, 10:19 UTC

Conversa de Mercado

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 de mai. de 2026, 10:05 UTC

Ganhos

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 de mai. de 2026, 10:04 UTC

Ganhos

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 de mai. de 2026, 10:03 UTC

Ganhos

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 de mai. de 2026, 10:02 UTC

Ganhos

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 de mai. de 2026, 10:01 UTC

Ganhos

Tenaga Nasional 1Q Net Up 3.7% on Year

25 de mai. de 2026, 10:00 UTC

Ganhos

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q EPS MYR0.1883

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q Rev MYR17.1B

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q Net MYR1.1B

25 de mai. de 2026, 09:38 UTC

Conversa de Mercado

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 de mai. de 2026, 09:33 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

25 de mai. de 2026, 09:33 UTC

Conversa de Mercado

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 de mai. de 2026, 08:55 UTC

Conversa de Mercado

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparação entre Pares

Variação de preço

Ovid therapeutics Inc Previsão

Preço-alvo

By TipRanks

115.79% parte superior

Previsão para 12 meses

Média 5.33 USD 115.79%

Máximo 7 USD

Mínimo 4 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

159 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.